

Atogepant: Adis Evaluation

Key Points

- CGRP receptor antagonist developed by AbbVie for the prophylaxis of migraine
- Received its first approval on 28 September 2021 in the USA
- Approved for the preventive treatment of episodic migraine in adults

Summary

Atogepant (Qulipta™) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine.

In September 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults. The drug is also in phase 3 clinical development for the preventive treatment of migraine in various other countries.

This article summarizes the milestones in the development of atogepant leading to this first approval for the preventive treatment of episodic migraine in adults.

This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2021.